Adoptive T Regulatory Cell Therapy for Tolerance Induction

Current Transplantation Reports

Volumn 2, Issue 2, 2015, Pages 191-201

  Cabello Kindelan, Cecilia ^a   Mackey, Shane ^a   Bayer, Allison L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

IL 2; T cells; T regulatory cells; Tolerance; Transplantation

Indexed keywords

EID: 84973525806     PISSN: None     EISSN: 21963029     Source Type: Journal    
DOI: 10.1007/s40472-015-0058-5     Document Type: Article

References (117)

1. Fandrich F, Ungefroren H. Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives. Adv Exp Med Biol. 2010;654:641–65.
2. + T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol. 2008;128(1):23–30.
3. Li DS, Warnock GL, Tu HJ, Ao Z, He Z, Lu H, et al. Do immunotherapy and beta cell replacement play a synergistic role in the treatment of type 1 diabetes? Life Sci. 2009;85(15–16):549–56.
4. Martins L, Malheiro J, Henriques AC, Dias L, Dores J, Oliveira F, et al. Pancreas-kidney transplantation and the evolution of pancreatic autoantibodies. Transplant Proc. 2009;41(3):913–5.
5. Meloche RM. Transplantation for the treatment of type 1 diabetes. World J Gastroenterol. 2007;13(47):6347–55.
6. Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59(4):947–57.
7. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5(2):e38.
8. − precursors. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2004;4(10):1614–27.
9. Gupta S, Shang W, Sun Z. Mechanisms regulating the development and function of natural regulatory T cells. Arch Immunol Ther Exp. 2008;56(2):85–102.
10. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061–70.
11. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921–8.
12. Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proceedings of the Royal Society of London Series B, containing papers of a Biological character Royal Society. 1954;143(910):58–80.
13. June CH. Adoptive T, cell therapy for cancer in the clinic. J Clin Invest. 2007;117(6):1466–76.
14. Pedrazzoli P, Comoli P, Montagna D, Demirer T, Bregni M, Ebmt S. Is adoptive T-cell therapy for solid tumors coming of age? Bone Marrow Transplant. 2012;47(8):1013–9.
15. Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, et al. Infectious transplantation tolerance. Science. 1993;259(5097):974–7.
16. Waldmann H, Adams E, Fairchild P, Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol Rev. 2006;212:301–13.
17. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–4.
18. Montes M, Rufer N, Appay V, Reynard S, Pittet MJ, Speiser DE, et al. Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. Clin Exp Immunol. 2005;142(2):292–302.
19. Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012;35(8):615–20.
20. Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, Kvalheim G, et al. Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. J Immunol Methods. 2010;355(1–2):52–60.
21. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology. 1970;18(5):723–37.
22. Gershon RK, Kondo K. Degeneracy of the immune response to sheep red cells. Thymic dependency. Immunology. 1972;23(3):335–42.
23. + suppressor cell and its mechanisms of action. J Exp Med. 1990;171(1):141–57. This study was the first to demonstrate that CD4+CD25+ cells were capable of mediating transplantation tolerance in mice.
24. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151–64. This study demonstrated that CD4+CD25+ cells function in controlling peripheral tolerance and development of autoimmunity in mice.
25. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62.
26. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18–32.
27. + regulatory T cells. Nat Immunol. 2003;4(4):330–6.
28. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–61.
29. + T regulatory cells. Nat Immunol. 2003;4(4):337–42.
30. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184(2):387–96.
31. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162(9):5317–26.
32. Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H. Both CD4(+)CD25(+) and CD4(+)CD25(−) regulatory cells mediate dominant transplantation tolerance. J Immunol. 2002;168(11):5558–65.
33. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001;166(6):3789–96.
34. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol. 2002;168(3):1080–6.
35. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest. 2006;116(5):1371–81.
36. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med. 2002;195(12):1641–6.
37. + regulatory T-cells. Diabetes. 2008;57(9):2341–7.
38. Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes. 2009;58(10):2277–84.
39. Vergani A, D’Addio F, Jurewicz M, Petrelli A, Watanabe T, Liu K, et al. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes. 2010;59(9):2253–64.
40. + T regulatory cells suppress autoimmunity while establishing transplantation tolerance. J Immunol. 2006;176(12):7149–53.
41. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant. 2002;8(10):525–35.
42. Pilat N, Baranyi U, Klaus C, Jaeckel E, Mpofu N, Wrba F, et al. Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplan Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(4):751–62.
43. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493–9.
44. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.
45. Shevach EM, McHugh RS, Thornton AM, Piccirillo C, Natarajan K, Margulies DH. Control of autoimmunity by regulatory T cells. Adv Exp Med Biol. 2001;490:21–32.
46. Roncarolo MG, Gregori S, Lucarelli B, Ciceri F, Bacchetta R. Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev. 2011;241(1):145–63.
47. + regulatory T cells. Microbes Infect Institut Pasteur. 2005;7(7–8):1066–72.
48. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389–99.
49. Zeng D, Lan F, Hoffmann P, Strober S. Suppression of graft-versus-host disease by naturally occurring regulatory T cells. Transplantation. 2004;77(1 Suppl):S9–S11.
50. + regulatory T cells suppress effector T cell proliferation. Clin Immunol. 2005;115(1):3–9.
51. Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83):83ra41.
52. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009;58(3):652–62.
53. Trzonkowski P, Szarynska M, Mysliwska J, Mysliwski A. Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytom A. 2009;75(3):175–88.
54. + T reg cells. J Exp Med. 2006;203(7):1701–11.
55. (low/neg) regulatory T cells. Methods Mol Biol. 2012;806:287–99.
56. Yu N, Li X, Song W, Li D, Yu D, Zeng X, et al. CD4(+)CD25 (+)CD127 (low/−) T cells: a more specific Treg population in human peripheral blood. Inflammation. 2012;35(6):1773–80.
57. − T regulatory cells. Clin Immunol. 2009;133(1):22–6.
58. Juvet SC, Whatcott AG, Bushell AR, Wood KJ. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am J Transplant. 2014;14(4):750–63.
59. Marek-Trzonkowska N, Mysliwec M, Siebert J, Trzonkowski P. Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes. 2013;14(5):322–32.
60. − regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care. 2012;35(9):1817–20. This trial provided evidence for using ex vivo expanded T regulatory cells for the treatment of type 1 diabetes.
61. − T regulatory cells prolongs survival of pancreatic islets in type 1 diabetes in children. Chicago: 2013 ADA Annual Meeting; 2013.
62. − regulatory T cells prolongs survival of pancreatic islets—results of one year follow-up. Clin Immunol. 2014;153(1):23–30.
63. Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplan Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(11):3010–20.
64. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3(83):83ra42.
65. Veerapathran A, Pidala J, Beato F, Betts B, Kim J, Turner JG, et al. Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood. 2013;122(13):2251–61.
66. Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 2011;118(20):5671–80.
67. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-2. Immunity. 2002;17(2):167–78. This study demonstrated the main non-redundant role of IL-2 is in the production of T regulatory cells.
68. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199(11):1455–65.
69. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004;199(11):1467–77.
70. + T lymphocytes. Blood. 2004;103(11):4216–21.
71. + regulatory T lymphocytes. Nat Med. 2008;14(1):88–92.
72. Tsang JY, Tanriver Y, Jiang S, Leung E, Ratnasothy K, Lombardi G, et al. Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression. Transpl Immunol. 2009;21(4):203–9.
73. Velasquez-Lopera MM, Eaton VL, Lerret NM, Correa LA, Decresce RP, Garcia LF, et al. Induction of transplantation tolerance by allogeneic donor-derived CD4(+)CD25(+)Foxp3(+) regulatory T cells. Transpl Immunol. 2008;19(2):127–35.
74. + regulatory T cells. Transplantation. 2006;82(12):1749–55.
75. Cabello-Kindelan C, de la Barrera A, Malek TR, Bayer AL. In vivo environment necessary to support transplanted donor mouse T regulatory cells. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2014;14(5):1032–45.
76. Duarte JH, Zelenay S, Bergman ML, Martins AC, Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol. 2009;39(4):948–55.
77. + T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A. 2009;106(6):1903–8.
78. + regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One. 2012;7(4):e35572.
79. Seddon B, Mason D. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity. J Exp Med. 1999;189(5):877–82.
80. Apostolou I, Sarukhan A, Klein L, von Boehmer H. Origin of regulatory T cells with known specificity for antigen. Nat Immunol. 2002;3(8):756–63.
81. + regulatory T cells. J Immunol. 2003;171(11):5678–82.
82. + immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12(4):431–40.
83. + regulatory T cells. J Immunol. 2003;171(7):3348–52.
84. + regulatory T cells including suppressors of alloreactivity. Immunol Rev. 2006;212:314–29.
85. + regulatory T cells by antigen-processing dendritic cells. J Exp Med. 2003;198(2):235–47.
86. Markees TG, Serreze DV, Phillips NE, Sorli CH, Gordon EJ, Shultz LD, et al. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes. 1999;48(5):967–74.
87. Pearson T, Markees TG, Serreze DV, Pierce MA, Marron MP, Wicker LS, et al. Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J Immunol. 2003;171(1):185–95.
88. Pearson T, Markees TG, Wicker LS, Serreze DV, Peterson LB, Mordes JP, et al. NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes. 2003;52(2):321–6.
89. + regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med. 2007;204(1):191–201.
90. + T cell numbers. J Immunol. 2002;169(9):4850–60.
91. + T regulatory cell development during the neonatal period. J Exp Med. 2005;201(5):769–77.
92. + T regulatory cells. J Immunol. 2007;178(7):4062–71.
93. + regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol. 2005;6(11):1152–9.
94. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6(11):1142–51.
95. + regulatory T cell function. J Exp Med. 2002;196(6):851–7.
96. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201(5):723–35.
97. + T cells: evidence for two distinct regulatory mechanisms. Eur J Immunol. 2001;31(6):1637–45.
98. Bayer AL, Pugliese A, Malek TR. The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res. 2013;57(1–3):197–209.
99. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4(9):665–74.
100. Bayer AL, Chirinos J, Cabello C, Yang J, Matsutani T, Malek TR, et al. Expansion of a restricted residual host T reg-cell repertoire is dependent on IL-2 following experimental autologous hematopoietic stem transplantation. Eur J Immunol. 2011;41(12):3467–78.
101. Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity. 2009;30(2):204–17.
102. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010;207(9):1871–8.
103. Rosenzwajg M, Churlaud G, Hartemann A, Klatzmann D. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes. Curr Diabetes Rep. 2014;14(12):553.
104. Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, Trebeden-Negre H, et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I–II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol. 2009;35(3):569–81.
105. Long AS, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 2012. doi:10.2337/db12-0049. Published online before print June 20, 2012.
106. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067–77.
107. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1(4):295–305.
108. Kim HJ, Cantor H. Regulation of self-tolerance by Qa-1-restricted CD8(+) regulatory T cells. Semin Immunol. 2011;23(6):446–52.
109. Kim HJ, Verbinnen B, Tang X, Lu L, Cantor H. Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature. 2010;467(7313):328–32.
110. + T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice. Proc Natl Acad Sci U S A. 2011;108(5):2010–5.
111. + regulatory T cells. J Clin Invest. 2013;123(3):1382–9.
112. + Treg—from mouse to man. Blood. 2013;122(21):3474.
113. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12 months results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013;1(4):306–16.
114. Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(9):2132–41.
115. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity. 2009;31(4):654–64.
116. Gasteiger G, Hemmers S, Firth MA, Le Floc’h A, Huse M, Sun JC, et al. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med. 2013;210(6):1167–78.
117. Sitrin J, Ring A, Garcia KC, Benoist C, Mathis D. Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med. 2013;210(6):1153–65.